Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 30, 2023

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Brain MetastasesNonsmall Cell Lung Cancer Stage III
Interventions
DIAGNOSTIC_TEST

MRI of the Brain

An MRI brain scan with and without gadolinium contrast. Three scans are planned for each participant.

OTHER

Blood draws

Before each MRI, participants will give about a teaspoon of blood to test for clinical purposes.

OTHER

Quality of Life Questionnaires

Participants will fill out two questionnaires about their health. These questionnaires will tell investigators about any symptoms participants may be having that might be related to cancer spreading to their brain. This will take about 10-15 minutes to complete.

DRUG

Gadolinium

Given intravenously

Trial Locations (1)

27157

RECRUITING

Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER